WATERS CORP (WAT)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for WAT
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WAT | Independent Director | 68 | ["Deep scientific knowledge","International and operational experience in the pharmaceutical sector","Leadership in the biopharmaceutical industry for more than 30 years","Successful oversight of drug and therapy research and development","Oversaw a Novartis-backed biopharmaceutical startup","Recognized as an innovative science leader"] | ["Science and Technology (Chair)","Nominating and Corporate Governance"] | 2026 |
Biography sourced from the proxy statement filing.
Independent Director since 2021 Age: 68 COMMITTEES Science and Technology (Chair) Nominating and Corporate Governance Dr. Huang brings deep scientific knowledge, international and operational experience in the pharmaceutical sector to the Board, stemming from her more than 30 years of leadership in the biopharmaceutical industry. Successful oversight of numerous drug and therapy research, discovery, clinical trial and development phases in the biotech and pharma industry space. Responsible for overseeing a Novartis-backed biopharmaceutical startup through its global expansion. Widely recognized as an innovative science leader, named the PharmaVOICE100 list of most inspiring leaders in life sciences. CAREER HIGHLIGHTS Dunad Therapeutics President and CEO (2022 present) Cygnal Therapeutics CEO (2019 2022) Flagship Pioneering Venture Partner (2019 2022) F. Hoffman La-Roche, Ltd. SVP and Global Head, Therapeutic Modalities (2014 2018) GlaxoSmithKline plc VP and Global Head of Discovery Academic Partnerships (DPAc) Alternative Discovery and Development, (2012 2014) Beigene LTD Founder and CSO (2010 2012) Merck and Co. VP, Oncology Integrator, Discovery and Early Development (2006 2010) Held roles of increasing responsibility at Merck & Co. Inc. and GlaxoSmithKline plc OTHER PUBLIC COMPANY BOARDS BB Biotech AG (SWX: BION) (2022 present) FORMER (PAST 5 YEARS) None EDUCATION BS, Biology, MIT Ph.D., Molecular Biology, Princeton University